Results 211 to 220 of about 199,032 (289)
Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang +13 more
wiley +1 more source
Synergistic immunomodulation: integrating physical ablation with immune checkpoint inhibitors for metastatic colorectal carcinoma. [PDF]
Shi X, Wu C, Deng W.
europepmc +1 more source
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin +11 more
wiley +1 more source
Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications. [PDF]
Wu F, Danzeng Q, Wu R, Shen Y, Shi G.
europepmc +1 more source
ABHD17C‐mediated depalmitoylation of BCL6B at Cys442 blocks its nuclear import and triggers ubiquitin‐dependent degradation, attenuating transcriptional repression of the anti‐phagocytic signal CD24. This mechanism enables pancreatic cancer cells to evade macrophage phagocytosis and fosters an immunosuppressive microenvironment.
Yalu Zhang +9 more
wiley +1 more source
A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors. [PDF]
Bertucci A +4 more
europepmc +1 more source
Reprogramming the Immune Landscape of Inflammatory Breast Cancer
Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez +3 more
wiley +1 more source
Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities. [PDF]
Wen H, Qi Y, Song J, Yan X.
europepmc +1 more source

